Journal of Ethnic Foods

Similar documents
Flu, Avian Flu and emerging aspects (H1N1 resistance)

Influenza virus.

INFLUENZA. Rob Young (James. J. Reid) Faculty of Medicine University of Auckland (Otago)

Influenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics

INFLUENZA VIRUS. Influenza virus

Antiviral Research xxx (2005) xxx xxx. Short communication

Supporting Information

INFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE

Influenza A H1N1 HA ELISA Pair Set

10 3 pfu A B 2004/ FluA. Viral Shedding. Viral Shedding. Frank Houston Family Study 2005/

Ralph KY Lee Honorary Secretary HKIOEH

An Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes. Nick Poulton June September 2012

Understanding mortality from pandemic and seasonal influenza

1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination

Patricia Fitzgerald-Bocarsly

Influenza: The Threat of a Pandemic

Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010

Ralf Wagner Paul-Ehrlich-Institut

Antiviral Activity of the Plant Extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii Against Influenza Virus A/PR/8/34

Heat-killed Lactobacillus casei

WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update

Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans

Influenza virus.

J.A.L. Ives a, *, J.A. Carr a, D.B. Mendel b, C.Y. Tai b, R. Lambkin c,1, L. Kelly c, J.S. Oxford c, F.G. Hayden d, N.A. Roberts a. 1.

2009 (Pandemic) H1N1 Influenza Virus

Reassortment of influenza A virus genes linked to PB1 polymerase gene

6.2 Pandemic influenza

Evolution of influenza

Acute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).

PUBLIC HEALTH SIGNIFICANCE SEASONAL INFLUENZA AVIAN INFLUENZA SWINE INFLUENZA

A study of oseltamivir-resistant influenza viruses in Thailand,

Cristina Cassetti, Ph.D.

Supporting Information

Influenza 2009: Not Yet The Perfect Storm

Transforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago

Pandemic Influenza influenza epidemic: realization of a worst-case scenario

Application Note Soy for Isoflavones by HPLC. Botanical Name: Glycine max L. Common Names: Parts of Plant Used: Beans.

Running head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1

The Diabetes Epidemic in Korea

Diagnosing and managing

Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set

Prophylaxis and Treatment for Influenza among the Elderly

INFLUENZA EVOLUTION: Challenges for diagnosis

TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?

2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit

Detection of neuraminidase-inhibiting antibodies for measurement of Influenza vaccine immunogenicity

Influenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong

INFLUENZA VACCINATION AND MANAGEMENT SUMMARY

Overview: Chapter 19 Viruses: A Borrowed Life

Avian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center

Influenza. Gwen Clutario, Terry Chhour, Karen Lee

Cloudbreak. March Cidara Therapeutics

ECDC TECHNICAL REPORT

Cloudbreak. January Cidara Therapeutics

Antiviral-resistant B viruses with a novel mutation detected by antiviral resistance surveillance in Japan

VIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks

Detection and management of antiviral resistance for influenza viruses

Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients

Age Distribution of Influenza and Pneumonia Mortality in the United States,

Late diagnosis of influenza in adult patients during a seasonal outbreak

Incorporating virologic data into seasonal and pandemic influenza vaccines

(the change introduced is to add a risk assessment, missing from the previous version, for small-scale laboratory work with characterized CVV)

Current Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?

Unit 2: Lesson 2 Case Studies: Influenza and HIV LESSON QUESTIONS

Influenza: The past, the present, the (future) pandemic

Public health relevant virological features of Influenza A(H7N9) causing human infection in China

Cover Page. The handle holds various files of this Leiden University dissertation

in control group 7, , , ,

Changes in the seroprevalence of IgG anti-hepatitis A virus between 2001 and 2013: experience at a single center in Korea

External quality assessment for influenza antiviral susceptibility for the European Reference Laboratory Network for human influenza

Update on influenza monitoring and vaccine development

STUDIES UPON THE POSSIBILITIES OF AVIAN INFLUENZA VIRUSES CULTIVATION IN CHICK EMBRYOS AT DIFFERENT AGE

ORTHOMYXOVIRUSES INFLUENZA VIRUSES. (A,B and C)

: Ajou University College of Medicine, Suwon, Korea; Ajou University College of Medicine, Graduate

Q: If antibody to the NA and HA are protective, why do we continually get epidemics & pandemics of flu?

Before and during influenza pandemics

NEXT GENERATION SEQUENCING OPENS NEW VIEWS ON VIRUS EVOLUTION AND EPIDEMIOLOGY. 16th International WAVLD symposium, 10th OIE Seminar

TREATING MEXICAN (NOVEL) INFLUENZA IN AN IMMUNOCOMPROMISED PATIENT

What s New in Flu? An Update on Influenza Prevention and Treatment

HS-LS4-4 Construct an explanation based on evidence for how natural selection leads to adaptation of populations.

Reagents for the Typing of Human Influenza Isolates 2011

Kazumi YAGASAKI, Masato NAGAOKA and Yutaka MIURA

Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines

Cluster-Randomized Controlled Trial of a Brief Theory-Based Avian Influenza Prevention Program for Poultry Workers in Taiwan

Influenza or flu is a

Situation Update Pandemic (H1N1) August 2009

Early Diagnosis: A Critical Step in Bird Flu Prevention

Nanoparticulate Vaccine Design: The VesiVax System

Outbreaks and control of swine influenza viruses in Korea

Alkaline Phosphatase Assay Kit (Fluorometric)

SCIENTIFIC DISCUSSION

Influenza Virus Genotypes Circulating In Central Greece During And Vaccine Strain Match

Brief Definitive Report

Bangladesh J. Bot. 46(4): , 2017 (December)

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today

STANDARD OPERATING PROTOCOL (SOP)

Avian Influenza: Outbreak in Spring 2015 and Preparing for Fall

AVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.

Journal of Negative Results in BioMedicine 2011, 10:5

Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease

Transcription:

J Ethn Foods 2 (2015) 47e51 Contents lists available at ScienceDirect Journal of Ethnic Foods journal homepage: http://journalofethnicfoods.net Original article Antiviral activity of Chongkukjang extracts against influenza A virus in vitro and in vivo Bai Wei a, *, Se-Yeoun Cha a, *, Min Kang a, Young Jin Kim b, Chang-Won Cho b, Young Kyoung Rhee b, Hee-Do Hong b, Hyung-Kwan Jang a, * a Departments of Infectious Diseases and Avian Diseases, College of Veterinary Medicine and Korea Zoonosis Research Institute, Chonbuk National University, Iksan, Jeollabuk-do, South Korea b Korea Food Research Institute, Songnam, Kyongki-do, South Korea article info abstract Article history: Available online 5 May 2015 Keywords: antiviral effect Chongkukjang extracts influenza virus neuraminidase inhibitory activity Background: Chongkukjang is a traditional Korean fermented product prepared from soybeans and reported to have multiple biological functions, including antidiabetic, antiinflammatory, and neuroprotective effects. Influenza is a respiratory disease caused by influenza viruses and continues to be a worldwide threat with a high potential to cause pandemics. Besides vaccination, only two classes of drugs are available for antiviral treatment against these pathogens. Methods: We tested the inhibitory activity of an ethyl acetate extract from Chongkukjang toward influenza A virus neuraminidase. Results: All 10 compounds extracted from Chongkukjang showed neuraminidase inhibitory activity. Extracts A3 and A8, with high neuraminidase content, had the best inhibitory activities. The in vivo antiinfluenza virus activities of the ethyl acetate, A3, and A8 extracts as well as commercially available genistein were evaluated using H1N1 (A/NWS/33) to test mice survivability after virus challenge. The Chongkukjang extracts did not reduce mortality, but the A3 and A8 extracts delayed the median time to death after influenza A virus infection of mice. Conclusion: Our results suggest that the Chongkukjang extracts may have potential as a therapeutic agent to treat influenza virus infection. Copyright 2015, Korea Food Research Institute, Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction Chongkukjang is a fermented product manufactured by shortterm fermentation of soybean using Bacillus subtilis that contains many microorganisms and bioactive compounds that are absent from unfermented soybeans (Fig. 1) [1e3]. Flavonoid glycosides are converted into aglycones by hydrolysis during fermentation of Chongkukjang, and many of the proteins are degraded into small peptides and amino acids [4]. Koreans have been consuming Chongkukjang for hundreds of years, and most believe that Chongkukjang consists of proteins and minerals that promote the generation and growth of human cells and strengthen the immune * Corresponding author. Departments of Infectious Diseases and Avian Diseases, College of Veterinary Medicine and Korea Zoonosis Research Institute, Chonbuk National University, 79 Gobong-ro, Iksan 570e752, Jeollabuk-do, South Korea. E-mail address: hkjang@jbnu.ac.kr (H.-K. Jang). * B. Wei and S.-Y. Cha contributed equally to this study. system [5,6]. Chongkukjang has multiple functions, including antidiabetic, antiinflammatory, and neuroprotective effects [5,7]. Influenza viruses are respiratory pathogens that affect humans and are responsible for substantial morbidity, mortality, and decreased productivity worldwide [8]. Influenza viruses contain two glycoproteins on their surface, hemagglutinin (HA) and neuraminidase (NA), which recognize sialic acid in hostecell glycoconjugates. HA binds to terminal sialic acid groups on cell surface glycoconjugates, leading to attachment and subsequent penetration of virus into cells, and NA exhibits enzymatic activity that removes sialic acid from glycoconjugates, facilitating the release of progeny virions from infected cells and preventing the aggregation of progeny virions [9]. Neuraminidase inhibitors (NAIs) act by binding to the active site of the viral NA enzyme and preventing release and spread of progeny virions from infected cells during the replication cycle [10]. NAIs block the neuraminidase active site and prevent release and spread of new virions [11]. NA was chosen as a suitable drug target because it plays a major role in the propagation of influenza viruses, and the amino acid residues of the active site http://dx.doi.org/10.1016/j.jef.2015.04.001 2352-6181/Copyright 2015, Korea Food Research Institute, Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

48 J Ethn Foods 2015; 2: 47e51 determined using a VICTOR X4 Multilabel Plate Reader (PerkinElmer Inc., Waltham, MA, USA) at an excitation wavelength of 360 nm and an emission wavelength of 448 nm. The appropriate concentration of virus for use in the NA inhibition assay was determined by selecting a dilution of virus in the linear portion of the enzyme activity curve. Zanamivir was obtained from Sigma and used as a positive control. This assay was performed in duplicate for each isolate, and the half-maximal inhibitory concentration (IC 50 ) value for each virus and for each antiviral agent was determined. The IC 50 is the antiviral agent concentration that inhibits 50% of neuraminidase activity. 2.3. Isolation of an active component from Chongkukjang Fig. 1. Chongkukjang is a traditional Korean fermented product prepared from soybean. Chongkukjang is manufactured via the short-term fermentation of soybeans using Bacillus subtilis. interacting directly with the substrate or surrounding the central active site of the enzyme are strictly conserved [12]. Treating influenza with NAIs has become the most popular treatment among primary care doctors. NAIs were introduced to clinical practice in 1999, but so far only zanamivir and oseltamivir have been licensed for use in humans [13]. Unfortunately, viruses resistant to zanamivir and oseltamivir have been generated in vitro and in humans recently [14]. This highlights the urgent need for new and readily available antiinfluenza agents. In the present study, we investigated the antiinfluenza activities of Chongkukjang extracts and demonstrated their efficacy. 2. Materials and methods 2.1. Viruses The influenza virus used in this study (Influenza A/NWS/33; Influenza A/chicken/Korea/MS96/96) was propagated in the allantoic sac of 10-day-old specific pathogen-free embryonated eggs. These virus stocks were frozen at 80 C until use. Viral HA units were determined in 96-well microtiter plates using 1% chicken red blood cells. 2.2. Fluorometric neuraminidase activity assay A fluorescence-based NA inhibition assay was used to determine the sensitivity of the viruses to NAIs. The assay is based on the release of a 4-methylumbelliferone fluorescent product from the 2- (4-methylumbelliferyl)-a-d-N-acetylneuraminic acid (MUNANA) substrate (Sigma, St. Louis, MO, USA) as a measure of NA activity. The NA activity assay was carried out to determine the dilution of each virus to be used in the subsequent NA inhibition assay. Twofold dilutions of virus in assay buffer (32.5mM MES [2-(N-morpholino)ethanesulfonic acid], ph 6.5, 4mM CaCl 2 with 0.1% NP-40, and 0.3 mg/ml bovine serum albumin) were prepared, mixed with an equal volume (50 ml) of MUNANA substrate (0.3mM), and incubated at 37 C for 60 minutes. The reaction was terminated by adding 100 ml stop solution (0.14M NaOH in 83% ethanol). The fluorometric quantification of 4-methylumbelliferone was Commercial Chongkukjang samples were obtained from Sunchang MoonOkrae Food (Sunchang, Korea), and the extracts were prepared by the Korea Food Research Institute. Briefly, Chongkukjang was extracted with ethanol, and the liquid was removed by evaporation. The residue was suspended and successively partitioned in fractions of ethyl acetate, butanol, and water. The total crude extract was dissolved in CH 2 Cl 2 /H 2 O (95:5), and the ethyl acetate fraction was subjected to silica open-column chromatography. The mobile phase solvent was dichloromethane/ethanol diluted as 95:5, 90:10, 80:20, and 50:50. All 10 subfractions were combined (A1eA10) based on thin-layer chromatography analysis. 2.4. Animal model and experimental design Female (weight, 17e19 g) 6-week-old specific pathogen-free BALB/c mice (Daejeon, Chungnam, Korea) were used. The mice were quarantined 24 hours prior to use. The AIN-93M diet was provided as feed throughout the experiment, as recommended by the American Institute of Nutrition [15]. All animals received humane care in compliance with the National Association of Laboratory Animal Care and were fed in isolation (Three-Shine, Daejeon, Korea). To investigate the safety of the Chongkukjang extract in mice, the mice were administered the ethyl acetate, A3, and A8 fractions, as well as genistein (0.4 g/kg/d of body weight). Phosphatebuffered saline was given to the normal control group. The mice were divided into groups of 10 each, and the treatments were carried out for 14 days. Clinical signs were recorded daily, and the body weight was measured on Days 0, 7, 10, and 14. To investigate the protective activity of the Chongkukjang extracts against lethal influenza virus in vivo, the mice were divided into groups of 10 each. The inoculated mice received the ethyl acetate, A3, and A8 extracts as well as genistein (0.2 and 0.4 g/kg/d), respectively. The treatments were administered daily via gavages for 6 days before challenge and 14 days after influenza A virus challenge. Studies with mice were performed as described previously, and phosphate-buffered saline was used as the negative control. The mice were anesthetized with diethyl ether and exposed to 0.1 ml virus by intranasal instillation. A viral challenge dose of 10 7.0 50% embryo infectious dose (EID 50 )/0.1 ml (A/NWS/ 33), which was approximately 80e90% of the lethal dose, was used. Mice were observed daily for 14 days after infection. The protective effect was estimated by preventing death and prolonging the median time to death (MTD). 2.5. Data analysis Data are expressed as the mean ± standard deviation of at least three independent experiments. Body weight was analyzed with one-way analysis of variance [16]. Statistical analyses were

B. Wei et al / Chongkukjang extracts against influenza A virus 49 performed using the SPSS software (SPSS Inc., Chicago, IL, USA). A p value <0.05 was considered statistically significant. 3. Results 3.1. Inhibitory effect of the Chongkukjang extracts on influenza virus in vitro The standard soybean isoflavones, such as daidzin, daidzein, genistin, genistein, glycitin, and glycitein (Sigma), were applied to the fluorometric NA activity assay, and genistein showed the best NA inhibitory effect compared with that of the five other standard soybean isoflavones (data not shown). Thus, genistein was used to control the extract composition of the Chongkukjang eluent at each step. NA is one of the most important targets to screen antiinfluenza virus A drugs. We first investigated whether the Chongkukjang fractions exerted antiviral action. The ethyl acetate, butanol, and water fractions were measured using the fluorometric NA activity assay. The ethyl acetate fraction showed the best NA inhibitory effect compared with that of butanol and water (data not shown). Thus, the ethyl acetate fraction was used for further purification. The Chongkukjang extracts were dose-dependently effective against influenza A virus, and the calculated IC 50 values of the extracts against the influenza virus are shown in Table 1. The A3 extract showed the best NA inhibitory effect against influenza A virus. The A8 extract also showed a high inhibitory effect. The Chongkukjang extract seemed to be more effective against A/NWS/ 33 (H1N1) than against A/chicken/Korea/MS96/9 (H9N2). Genistein showed similar effects against A/NWS/33 (H1N1) and A/chicken/ Korea/MS96/96 (H9N2). 3.2. Inhibitory effect of the Chongkukjang extracts on the influenza virus in vivo We next tested whether the Chongkukjang extract, which inhibited NA activity, could relieve a viral infection in vivo. First, we assessed the safety of the Chongkukjang extract in mice. Animals treated with the Chongkukjang extract maintained a relatively steady weight, and mean body weights of the treated mice, except the A8 group, were higher than those of the control group, but no significant differences were observed throughout the study (Table 2). No clinical symptoms were observed throughout the study. To investigate the protective effect of the Chongkukjang extract in vivo, groups of mice were inoculated with 10 7.0 EID 50 /0.1 ml A/ NWS/33 (H1N1). All of the mice that received the ethyl acetate, A3, and A8 extracts as well as genistein (0.4 g/kg/d) died within the experimental period (data not shown). The results for mice that received a dose of 0.2 g/kg/d are shown in Fig. 2. About 10% of the Table 1 Inhibitory effect of the Chongkukjang extracts against influenza A virus.* No. Compound NA inhibitory effect, IC 50 (mg/ml) A/NWS/33 (H1N1) A/chicken/Korea/MS96/ 96 (H9N2) 1 Ethyl acetate 8,482.5 ± 124.3 14,264.2.5 ± 1,183.1 extract 2 A3 17,611.1 ± 3,052.7 28,242.4 ± 2,571.5 3 A8 4,565.9 ± 66.9 8,949.3 ± 974.3 4 Genistein 30,58.8 ± 218.9 2,729.6 ± 275.1 IC 50, drug concentration required to inhibit half of neuraminidase activity. * Fluorescence-based neuraminidase (NA) inhibition assay was used to determine the sensitivity of influenza A viruses to Chongkukjang extracts. Table 2 Body weights (mean ± standard deviation) of the mice in each group.* Group Body weight (g) 0 DPI 7 DPI 10 DPI 14 DPI Negative 18.6 ± 0.5 18.6 ± 0.8 19.2 ± 0.8 19.7 ± 0.5 Ethyl acetate extract (0.4 g/kg) 17.9 ± 0.5 19.4 ± 0.6 20.3 ± 1.1 20.3 ± 1.2 A3 (0.4 g/kg) 18.0 ± 0.3 19.5 ± 1.0 20.4 ± 1.6 20.7 ± 1.9 A8 (0.4 g/kg) 18.1 ± 0.7 18.7 ± 0.5 19.2 ± 0.8 19.7 ± 0.4 Genistein (0.4 g/kg) 17.9 ± 0.4 18.7 ± 0.8 19.4 ± 1.4 20.5 ± 1.1 DPI, days post inoculation. * Safety of the Chongkukjang extract in mice administered with ethyl acetate, A3, and A8 fractions, as well as genistein (0.4 g/kg/d of body weight) for consecutive 14 days. mice from the positive control group survived until the end of the experiment. All challenge groups, except the genistein group (0.2 g/ kg) and the A3 group (0.2 g/kg), died by 8 days after infection. The MTD of the mice treated with the A3 and A8 (0.2 g/kg) extracts was 5 and 6 days, which was longer than that of the viral control group (3 days). The survival rate in the A3 group (0.2 g/kg) at 14 days post infection was 20%, which was higher than that of the viral control group (10%). 4. Discussion There is an urgent medical need to develop new strategies against influenza virus infection. At the moment antiviral drugs are the only known defense against the disease, as no vaccine is available, which is similar to the early phase of a pandemic or when the prediction for the seasonal influenza vaccine composition fails. In 2010, the World Health Organization suggested the development of novel and effective treatment strategies for influenza virus including natural products [17]. This prompted us to investigate the antiviral activity of traditional food extracts against influenza virus infection. The goal of this study was to determine whether Chongkukjang extracts could function as an antiviral agent against influenza A virus, because Chongkukjang has a strong record in the literature for its beneficial effects on human health [12,18]. Our results suggest for the first time that the Chongkukjang extracts were active against the influenza A virus. Influenza virus NA is thought to be required to secrete newly synthesized virus from infected cells and to aid in the movement of the virus. NA can be administered relatively late in the viral infection and still render a significant antiviral effect [19]. Genistein showed a better effect than the A3 and A8 extracts against A/NWS/ 33 (H1N1) and A/chicken/Korea/MS96/96 (H9N2), suggesting that other active compounds may be present within this extract. This result agreed with those for the ethyl acetate fraction, which showed less efficiency than the further purified A3 and A8 extracts. Although the Chongkukjang extracts showed less activity than zanamivir and oseltamivir, Chongkukjang extracts showed possible research directions as a potential candidate for zanamivir- and oseltamivir-resistant cases in clinical practice. This provides a good backdrop considering that after 3 years of NAI use, it has been noted that 0.35% of isolates were found to have become resistantdin particular, higher percentages of such resistance have been observed in children [20,21]. Wide variations in the IC 50 for oseltamivir are observed in seasonal influenza A with or without the virus subtype [22]. Genistein has a weak NA inhibitory effect of about 20 mg/ml IC 50 against the H1N1 influenza A virus [23]. Our result showed about six times higher efficiency of the IC 50 against the same NA type of influenza A virus. An NA gene mutation (H274Y, H275Y in N1 numbering) has been associated with NA inhibitor susceptibility [24]. The

50 J Ethn Foods 2015; 2: 47e51 Fig. 2. The in vivo protective activities of the Chongkukjang extracts on lethal influenza A virus-infected mice. The treatments were administered daily via gavages for 6 days before challenge and 14 days after influenza A virus challenge. Cumulative survival curve for the indicated groups (n ¼ 10/group). Chongkukjang extracts showed a better inhibitory effect against A/ NWS/33 (H1N1) than that against A/chicken/Korea/MS96/96 (H9N2). This result agrees with the finding that avian isolates have significantly higher resistance to NAIs than that of human isolates [25]. It is not apparent how accurately the IC 50 values determined from the enzyme inhibition assay results reflect actual differences in inhibitor potency. Once efficacy is observed against an influenza virus, it is important to use a variety of other virus strains in followup evaluations to ascertain if the antiviral effect applies to all viral strains encountered in the clinic. As the Chongkukjang extracts showed antiviral effects in vitro,a mouse study was performed to determine the in vivo effects of the Chongkukjang extracts against influenza A virus. Treatment with the A3 and A8 (0.2 g/kg) extracts produced a modest inhibitory effect on influenza A virus replication in mice. Influenza virusinfected mice receiving the Chongkukjang extract treatment did not show reduced mortality, but the A3 and A8 extracts delayed the mice MTD after influenza A virus infection. This result shows that the Chongkukjang extract is a potential candidate to fight influenza A virus infection. The Chongkukjang-treated groups (except the A8 group) maintained a higher body weight compared with the control group, which agrees with previous reports that soybean-related products increase body weight and lower the risk of toxic side effects at a low concentration [14,26]. This extract may be a potent antiviral agent against influenza virus with no host toxicity. We found that the A3 and A8 Chongkukjang extracts had a potential inhibitory activity against influenza viruses. This study is another example showing how plant extracts are capable of inhibiting influenza A virus infection. This study addresses the latest developments in theoretical and experimental research on the properties of NA that are and will be driving antiinfluenza drug development today and in the near future. Two further research directions can be undertaken. One would be to further characterize and identify the antiviral compounds in the extracts. Nevertheless, it is also important to determine whether only one compound, several closely related compounds, or the composite activity of several different molecules is/are responsible for the observed antiviral activity and whether the activity is selective for influenza viruses. We clearly need to focus more attention on ethnic foods, not only for nutrition but also for the functionality they provide in disease control. Conflicts of interest The authors have no conflicts of interest to declare. Acknowledgments This study was supported by research grants from the Korea Food Research Institute (E0143003528). References [1] Shin D and Jeong DY. Korean traditional fermented soybean products (Jang). J Ethnic Foods 2015;2:1e6. [2] Su CL, Wu CJ, Chen FN, Wang BJ, Sheu SR and Won SJ. Supernatant of bacterial fermented soybean induces apoptosis of human hepatocellular carcinoma Hep 3B cells via activation of caspase 8 and mitochondria. Food Chem Toxicol 2007;45:303e14. [3] Kwon DY, Hong SM, Ahn IS, Kim MJ, Yang HJ and Park S. Isoflavonoids and peptides from meju, long-term fermented soybeans, increase insulin sensitivity and exert insulinotropic effects in vitro. Nutrition 2011;27:244e52. [4] Nakajima N, Nozaki N, Ishihara K, Ishikawa A and Tsuji H. Analysis of isoflavone content in tempeh, a fermented soybean, and preparation of a new isoflavone-enriched tempeh. J Biosci Bioeng 2005;100:685e7. [5] Choi YH, Lim H, Heo MY, Kwon DY and Kim HP. Anti-inflammatory activity of the ethanol extract of Chungkukjang, Korean fermented bean: 5-lipoxygenase inhibition. J Med Food 2008;11:539e43. [6] Choi JH, Chung MJ, Jeong DY and Oh DH. Immunostimulatory activity of isoflavone-glycosides and ethanol extract from a fermented soybean product in human primary immune cells. J Med Food 2014;17:1113e21. [7] Kim DJ, Jeong YJ, Kwon JH, Moon KD, Kim HJ, Jeon SM, Lee MK, Park YB and Choi MS. Beneficial effect of chungkukjang on regulating blood glucose and pancreatic beta-cell functions in C75BL/KsJ-db/db mice. J Med Food 2008;11: 215e23. [8] Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH and Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997;87:1944e50. [9] El Zowalaty ME, Bustin SA, Husseiny MI and Ashour HM. Avian influenza: virology, diagnosis and surveillance. Future Microbiol 2013;8:1209e27. [10] Colman PM, Hoyne PA and Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993;67:2972e80. [11] Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM and Penn CR. 4-Guanidino-2,4-dideoxy-2,3- dehydro-n-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide-range of influenza-a and influenza-b viruses in-vitro. Antimicrob Agents Chemother 1993;37:1473e9. [12] Varghese JN, Laver WG and Colman PM. Structure of the influenza-virus glycoprotein antigen neuraminidase at 2.9-a-resolution. Nature 1983;303: 35e40. [13] Pozo F, Lina B, de Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A and Meijer A. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol 2013;57:5e12. [14] Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, Kakugawa S, Le MT, Yamashita M, Furuta Y, Ozawa M and Kawaoka Y. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 2010;6:e1001079. [15] Reeves PG, Nielsen FH and Fahey GC. Ain-93 purified diets for laboratory rodents d final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the Ain-76a rodent diet. J Nutr 1993;123: 1939e51. [16] Gordon LV. One-way analysis of variance using means and standard deviations. Educ Psychol Meas 1973;33:815e6.

B. Wei et al / Chongkukjang extracts against influenza A virus 51 [17] Shapovalova N, Tam J, Shindo N and Briand S. WHO public health research agenda for influenza: tools for strategic communication during pandemic and inter-pandemic periods. Influenza Other Resp 2011;5:266e8. [18] Hwang IS, Kim JE, Lee YJ, Kwak MH, Go J, Son HJ, Kim DS and Hwang DY. Fermented soybean product (Cheonggukjang) improved some attributes of protein and growth hormone measurements in SpragueeDawley rats. Nutr Res 2014;34:355e67. [19] Liu CG, Eichelberger MC, Compans RW and Air GM. Influenza type-a virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995;69:1099e106. [20] Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50: 2395e402. [21] Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG and Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127e33. [22] Kim YJ, Narayanan S and Chang KO. Inhibition of influenza virus replication by plant-derived isoquercetin. Antivir Res 2010;88:227e35. [23] Liu AL, Wang HD, Lee SM, Wang YT and Du GH. Structureeactivity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 2008;16:7141e7. [24] Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS and Hayden FG. Roberts NA. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55: 307e17. [25] Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA and Webster RG. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 2010;84:9800e9. [26] Lee YJ, Kim JE, Kwak MH, Go J, Son HJ, Kim DS, Kang BC, Lee HS and Hwang DY. Toxicity of fermented soybean product (cheonggukjang) manufactured by mixed culture of Bacillus subtilis MC31 and Lactobacillus sakei 383 on liver and kidney of ICR mice. Lab Anim Res 2014;30:54e63.